<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;A01A&quot;,&quot;href&quot;:&quot;atc/A01A.md&quot;},{&quot;label&quot;:&quot;dexamethasone&quot;}]"></div>
<div class="pk-recnav" data-items="[{&quot;id&quot;:&quot;Dexamethasone_Calderin2025_reference&quot;,&quot;label&quot;:&quot;Calderin_2025_reference&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_dexamethasone/Dexamethasone_Calderin2025_reference.md&quot;,&quot;status&quot;:&quot;extracted \u00b7 stale&quot;,&quot;css&quot;:&quot;pk-badge--green&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Dexamethasone_Calderin2025v2_reference&quot;,&quot;label&quot;:&quot;Calderin_2025_2_reference&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_dexamethasone/Dexamethasone_Calderin2025v2_reference.md&quot;,&quot;status&quot;:&quot;extracted \u00b7 stale&quot;,&quot;css&quot;:&quot;pk-badge--green&quot;,&quot;here&quot;:false}]"></div>

# dexamethasone

- **generic name:** dexamethasone
- **ATC codes:** `A01AC02`, `C05AA09`, `D07AB19`, `D07CB04`, `D07XB05`, `D10AA03`, `H02AB02`, `R01AD03`, `S01BA01`, `S01CA01`, `S01CB01`, `S02BA06`, `S02CA06`, `S03BA01`, `S03CA01`
- **DrugBank:** [DB01234](https://go.drugbank.com/drugs/DB01234) · **PubChem:** [CID 5743](https://pubchem.ncbi.nlm.nih.gov/compound/5743)
- **molar mass:** 392.4611 g/mol (C22H29FO5) — DrugBank
- **groups:** approved, investigational, vet_approved

## About

Dexamethasone is a corticosteroid used for many conditions, including inflammation, autoimmune disease, several cancers and lymphomas, cerebral and macular edema, Addison's disease, and COVID-19. It is widely used, appears on the WHO essential medicines list, is approved for human and veterinary use, and is authorised in the European Union for indications such as multiple myeloma, uveitis, and COVID-19.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q422252](https://www.wikidata.org/wiki/Q422252) and the WHO ATC classification and the EMA medicines list; not checked by a person.</small>

## Molecules and molar masses

> The molar mass each model uses to convert mass to molar concentration and to form a metabolite molecule for molecule. Looked up, never estimated: DrugBank for the drug, the paper's own value or the PubChem entry matched to the paper's name for a metabolite.

| molecule | role | molar mass (g/mol) | formula | source | PubChem | records |
|---|---|---|---|---|---|---|
| dexamethasone | parent | 392.461 | C22H29FO5 | DrugBank | [5743](https://pubchem.ncbi.nlm.nih.gov/compound/5743) | Calderin_2025, Calderin_2025_2, Świerczek_2023 |

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-04 00:36 | 22:57 | 2/2/2 | 4/0/0 | 0/0/0 | 436,280/67,482 | ollama / qwen3.8:27b-mtp-q8_0 | 29 | 11/18 | 28/1 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--stale">stale</span> <span class="pk-badge pk-badge--green" title="re-read by gpt-oss:120b (confirmed, agreement 1.0). The first reading is what the record holds.">cross-checked ✓</span><br><sub>STALE — current validate: extracted</sub><br><sub>route_to: `engineer_replication`</sub> | [Calderin_2025_reference](drugs/drug_dexamethasone/Dexamethasone_Calderin2025_reference.md) | ▶ model + simulator | 1-compartment, oral | 4 | Calderin JM et al., Pharmacokinetics of Dexamethasone in Tu…, Clinical infectious disease… (2026) | [10.1093/cid/ciaf642](https://doi.org/10.1093/cid/ciaf642) |
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--stale">stale</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.333). The first reading is what the record holds.">cross-check: disputed</span><br><sub>STALE — current validate: extracted</sub><br><sub>route_to: `engineer_replication`</sub> | [Calderin_2025_2_reference](drugs/drug_dexamethasone/Dexamethasone_Calderin2025v2_reference.md) | ▶ model + simulator | 1-compartment, oral | 4 | Calderin JM et al., Pharmacokinetics of dexamethasone in tu…, medRxiv : the preprint serv… (2025) | [10.1101/2025.07.14.25331510](https://doi.org/10.1101/2025.07.14.25331510) |
| <span class="pk-badge pk-badge--orange">needs review</span> <span class="pk-badge pk-badge--stale">stale</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (partly confirmed, agreement 0.5). The first reading is what the record holds.">cross-check: partial</span><br><sub>STALE — current validate: needs_review</sub><br><sub>blocking: C6_cl_magnitude failed (ratio None)</sub><br><sub>route_to: `human_review`</sub> | [Gawarammana_2011_reference](drugs/drug_dexamethasone/Dexamethasone_Gawarammana2011_reference.md) | — | 1-compartment (no model) | 2 | Gawarammana IB et al., Medical management of paraquat ingestion, British journal of clinical… (2011) | [10.1111/j.1365-2125.2011.04026.x](https://doi.org/10.1111/j.1365-2125.2011.04026.x) |
| <span class="pk-badge pk-badge--orange">needs review</span> <span class="pk-badge pk-badge--stale">stale</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.167). The first reading is what the record holds.">cross-check: disputed</span><br><sub>STALE — current validate: needs_review</sub><br><sub>blocking: disposition incomplete — only clearance/elimination extracted — the engineer ne…</sub><br><sub>route_to: `human_review`</sub> | [Świerczek_2023_reference](drugs/drug_dexamethasone/Dexamethasone_wierczek2023_reference.md) | — | 1-compartment (no model) | 3 | Świerczek A et al., Anti-inflammatory effects of dexamethas…, Clinical and translational… (2023) | [10.1111/cts.13577](https://doi.org/10.1111/cts.13577) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--stale">stale</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.533). The first reading is what the record holds.">cross-check: disputed</span><br><sub>STALE — current validate: rejected</sub><br><sub>blocking: C8 unreachable/orphan compartment or unlinked metabolite</sub><br><sub>route_to: `human_review`</sub> | [Papathanasiou_2025_reference](drugs/drug_dexamethasone/Dexamethasone_Papathanasiou2025_reference.md) | — | 2-compartment (no model) | 3 | Papathanasiou T et al., Population Pharmacokinetics for Belanta…, Clinical pharmacokinetics (2025) | [10.1007/s40262-025-01508-1](https://doi.org/10.1007/s40262-025-01508-1) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--stale">stale</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.286). The first reading is what the record holds.">cross-check: disputed</span> <span class="pk-badge pk-badge--species" title="Animal study (horse), not measured in people (from an LLM reading of the title and abstract by gpt-6-luna, p(non-human) 1.00).">horse</span><br><sub>STALE — current validate: rejected</sub><br><sub>blocking: C9 clearance/volume outside physiological window (implausible magnitude — unit/…</sub><br><sub>route_to: `human_review`</sub> | [Yu_2026_reference](drugs/drug_dexamethasone/Dexamethasone_Yu2026_reference.md) | — | 1-compartment (no model) | 3 | Yu R et al., Meta-Analysis and Physiologically-Based…, Pharmaceutical research (2026) | [10.1007/s11095-026-04120-5](https://doi.org/10.1007/s11095-026-04120-5) |

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--species" title="In-vitro data (cells, tissue or microsomes), not measured in people (from an LLM reading of the title and abstract by gpt-6-luna, p(non-human) 1.00).">in vitro</span> | [Snaterse_2023_luciferase_activity](drugs/drug_dexamethasone/pd_Snaterse_2023_luciferase_activity.md) | luciferase activity ← dexamethasone · direct Emax (saturable) effect | — | Snaterse G et al., Androgen receptor mutations modulate ac…, Prostate cancer and prostat… (2023) | [10.1038/s41391-022-00491-z](https://doi.org/10.1038/s41391-022-00491-z) |
| <span class="pk-badge pk-badge--green">accepted (caveats)</span> <span class="pk-badge pk-badge--species" title="Animal study (horse), not measured in people (from an LLM reading of the title and abstract by gpt-6-luna, p(non-human) 1.00).">horse</span> | [Yu_2026_GLU](drugs/drug_dexamethasone/pd_Yu_2026_GLU.md) | glucose ← dexamethasone · indirect response — drug stimulates the production of glucose | model (no simulator) | Yu R et al., Meta-Analysis and Physiologically-Based…, Pharmaceutical research (2026) | [10.1007/s11095-026-04120-5](https://doi.org/10.1007/s11095-026-04120-5) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Zufferey_2024_duration_of_analgesia](drugs/drug_dexamethasone/pd_Zufferey_2024_duration_of_analgesia.md) | duration of analgesia ← dexamethasone · direct Emax (saturable) effect | — | Zufferey PJ et al., Dose-response relationships of intraven…, British journal of anaesthe… (2024) | [10.1016/j.bja.2023.12.021](https://doi.org/10.1016/j.bja.2023.12.021) |
| <span class="pk-badge pk-badge--green">accepted (caveats)</span> | [Świerczek_2023_IL_6](drugs/drug_dexamethasone/pd_wierczek_2023_IL_6.md) | IL-6 ← dexamethasone · indirect response — drug inhibits the production of IL-6 | model (no simulator) | Świerczek A et al., Anti-inflammatory effects of dexamethas…, Clinical and translational… (2023) | [10.1111/cts.13577](https://doi.org/10.1111/cts.13577) |
| <span class="pk-badge pk-badge--green">accepted (caveats)</span> | [Świerczek_2023_TNF](drugs/drug_dexamethasone/pd_wierczek_2023_TNF.md) | TNFα ← dexamethasone · indirect response — drug inhibits the production of TNFα | model (no simulator) | Świerczek A et al., Anti-inflammatory effects of dexamethas…, Clinical and translational… (2023) | [10.1111/cts.13577](https://doi.org/10.1111/cts.13577) |
| <span class="pk-badge pk-badge--orange">needs review</span> <span class="pk-badge pk-badge--species" title="Animal study (horse), not measured in people (from an LLM reading of the title and abstract by gpt-6-luna, p(non-human) 1.00).">horse</span> | [Yu_2026_CTS](drugs/drug_dexamethasone/pd_Yu_2026_CTS.md) | cortisol ← dexamethasone · indirect response — drug inhibits the production of cortisol | model (no simulator) | Yu R et al., Meta-Analysis and Physiologically-Based…, Pharmaceutical research (2026) | [10.1007/s11095-026-04120-5](https://doi.org/10.1007/s11095-026-04120-5) |

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=dexamethasone) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | blood-brain barrier | `ABCB1` inducer/inhibitor/substrate, `ABCG2` inhibitor, `SLCO1A2` inhibitor | DrugBank actor |
| absorption | kidney | `ABCB1` inducer/inhibitor/substrate | DrugBank actor |
| absorption | liver | `ABCB1` inducer/inhibitor/substrate, `ABCG2` inhibitor | DrugBank actor |
| absorption | mammary gland | `ABCG2` inhibitor | DrugBank actor |
| absorption | placenta | `ABCB1` inducer/inhibitor/substrate | DrugBank actor |
| absorption | skeletal muscle | <sub>named in DrugBank's ADME text</sub> | prose |
| absorption | small intestine | `ABCB1` inducer/inhibitor/substrate, `ABCG2` inhibitor, `SLCO1A2` inhibitor | DrugBank actor |
| absorption | testis | `ABCB1` inducer/inhibitor/substrate, `ABCG2` inhibitor | DrugBank actor |
| distribution | blood | `ALB` binder | DrugBank actor |
| metabolism | kidney | `CYP3A5` inducer/substrate | DrugBank actor |
| metabolism | liver | `CYP2A6` inducer, `CYP2B6` inducer, `CYP2C19` inducer, `CYP2C8` inducer, `CYP2E1` inducer, `CYP3A4` inducer/inhibitor/substrate, `CYP3A5` inducer/substrate, `CYP3A7` inducer/substrate | DrugBank actor |
| metabolism | lung | `CYP1A1` inducer/inhibitor | DrugBank actor |
| metabolism | small intestine | `CYP1A1` inducer/inhibitor, `CYP3A4` inducer/inhibitor/substrate, `CYP3A5` inducer/substrate | DrugBank actor |
| excretion | kidney | `ABCC2` inducer, `SLC22A8` substrate | DrugBank actor |
| excretion | liver | `ABCB11` inducer, `ABCC2` inducer | DrugBank actor |
| excretion | small intestine | `ABCC2` inducer | DrugBank actor |
| — | adrenal gland | `CYP11B1` inhibitor, `CYP17A1` inhibitor | DrugBank actor |
| — | testis | `CYP17A1` inhibitor | DrugBank actor |

<sub>Actors without a tissue in the table: ANXA1 (target), CYP3A43 (inducer), CYP4A11 (inducer), HSD11B1 (substrate), HSD11B2 (substrate), NOS2 (negative modulator), NR0B1 (stimulator), NR1I2 (target), NR3C1 (target).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 1173 matched, 85 returned
- **screened:** 4  ·  **relevant:** 4
- **records:** 6  ·  extracted 2  ·  needs_review 2  ·  rejected 2  ·  stale 6
- **scholar-agent fallback query used:** not captured

## Full text wanted

_11 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Song_2021.pdf` | Song D et al., Across-species meta-analysis of dexamet…, Biopharmaceutics & drug dis… (2021) | popPK | 10 | [10.1002/bdd.2266](https://doi.org/10.1002/bdd.2266) | [33638217](https://pubmed.ncbi.nlm.nih.gov/33638217) | The paper reports a cross-species PK model for dexamethasone with specific aggregate statistics (mean CL, CV, partition coefficient), but the specific numeric parameter values for individual species are not listed in the provided text. |
| `Wen_2024.pdf` | Wen J et al., Pharmacokinetics of Dexamethasone in Ch…, Journal of clinical pharmac… (2024) | popPK | 10 | [10.1002/jcph.6108](https://doi.org/10.1002/jcph.6108) | [39120865](https://pubmed.ncbi.nlm.nih.gov/39120865) | The paper describes a population pharmacokinetic model for dexamethasone, but the specific numeric parameter values (CL, V, etc.) are not present in the provided abstract text. |
| `Derendorf_1993.pdf` | Derendorf H et al., Receptor-based pharmacokinetic-pharmaco…, Journal of clinical pharmac… (1993) | pd | 5 | [10.1002/j.1552-4604.1993.tb03930.x](https://doi.org/10.1002/j.1552-4604.1993.tb03930.x) | [8440759](https://www.ncbi.nlm.nih.gov/pubmed/8440759) | metadata signals extractable PD data (pharmacodynamicmodel) |
| `Krzyzanski_2024.pdf` | Krzyzanski W et al., Pharmacodynamic Age Structured Populati…, Journal of pharmaceutical s… (2024) | pd | 5 | [10.1016/j.xphs.2023.10.040](https://doi.org/10.1016/j.xphs.2023.10.040) | [37926235](https://www.ncbi.nlm.nih.gov/pubmed/37926235) | metadata signals extractable PD data (Emax) |
| `Puisset_2004.pdf` | Puisset F et al., Dexamethasone as a probe for docetaxel…, Cancer chemotherapy and pha… (2004) | pgx | 8 | [10.1007/s00280-004-0823-0](https://doi.org/10.1007/s00280-004-0823-0) | [15133628](https://www.ncbi.nlm.nih.gov/pubmed/15133628) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Zhang_2022.pdf` | Zhang Y et al., A Systematic Review of Population Pharm…, European journal of drug me… (2022) | pgx | 8 | [10.1007/s13318-021-00737-6](https://doi.org/10.1007/s13318-021-00737-6) | [34985725](https://www.ncbi.nlm.nih.gov/pubmed/34985725) | metadata signals extractable PGX data (SLCO1B1, PK/PD-context) |
| `Farooq_2016.pdf` | Farooq M et al., CYP2D6 Is Inducible by Endogenous and E…, Drug metabolism and disposi… (2016) | pgx | 7 | [10.1124/dmd.115.069229](https://doi.org/10.1124/dmd.115.069229) | [26965986](https://www.ncbi.nlm.nih.gov/pubmed/26965986) | metadata signals extractable PGX data (CYP2D6, PK/PD-context) |
| `Nemoto_1995.pdf` | Nemoto N et al., Maintenance of phenobarbital-inducible…, Archives of biochemistry an… (1995) | pgx | 7 | [10.1006/abbi.1995.1048](https://doi.org/10.1006/abbi.1995.1048) | [7840637](https://www.ncbi.nlm.nih.gov/pubmed/7840637) | metadata signals extractable PGX data (Cyp2b, PK/PD-context) |
| `Shou_2008.pdf` | Shou M et al., Modeling, prediction, and in vitro in v…, Drug metabolism and disposi… (2008) | pgx | 7 | [10.1124/dmd.108.020602](https://doi.org/10.1124/dmd.108.020602) | [18669588](https://www.ncbi.nlm.nih.gov/pubmed/18669588) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Van_2018.pdf` | Van Veggel M et al., Clinical Pharmacokinetics and Pharmacod…, Clinical pharmacokinetics (2018) | pgx | 7 | [10.1007/s40262-017-0565-x](https://doi.org/10.1007/s40262-017-0565-x) | [28667459](https://www.ncbi.nlm.nih.gov/pubmed/28667459) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |
| `Hibino_2022.pdf` | Hibino H et al., Evaluation of hepatic CYP3A enzyme acti…, European journal of clinica… (2022) | pgx | 5 | [10.1007/s00228-022-03275-5](https://doi.org/10.1007/s00228-022-03275-5) | [35039908](https://www.ncbi.nlm.nih.gov/pubmed/35039908) | metadata signals extractable PGX data (CYP3A) |

<sub>queue written 2026-10-04T00:15:57.328658+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| PGx | Abduraman_2022 | not_relevant | 0 | 0 | The study investigates CYP inhibition by botanical products, not the effect of a gene variant on dexamethasone PK/PD. |
| PGx | Acikgöz_2009 | not_relevant | 0 | 0 | The paper studies the effect of dexamethasone as an enzyme inducer on diazepam metabolism in hepatocytes, not the pharmacogenomics of dexamethasone itself. |
| PGx | Adebodun_1993 | not_relevant | 0 | 0 | The study investigates cellular mechanisms of dexamethasone resistance in cell lines (membrane potential/volume) rather than pharmacokinetic or pharmacodynamic parameters in humans based on genetic variants. |
| PGx | Agarwal_2024 | not_relevant | 0 | 0 | The paper studies formononetin, not dexamethasone, and does not report pharmacogenomic effects on dexamethasone PK/PD. |
| PGx | Berlińska_2020 | not_relevant | 2 | 0 | The paper discusses general factors affecting dexamethasone suppression tests, including CYP3A4 metabolism, but does not report specific pharmacogenomic effects of gene variants on PK/PD parameters. |
| PGx | Bowden_1985 | not_relevant | 0 | 0 | The paper investigates the lipolytic effects of human growth hormone preparations and does not report any pharmacogenomic effects on the pharmacokinetics or pharmacodynamics of dexamethasone. |
| PGx | Bullock_1995 | not_relevant | 0 | 0 | The study investigates enzyme induction in cynomolgus monkeys and does not report pharmacogenomic effects of human gene variants on dexamethasone PK/PD. |
| PGx | Cribb_1995 | not_relevant | 0 | 0 | The paper investigates the metabolism of sulfamethoxazole, not dexamethasone. |
| popPK | Czock_2005 | irrelevant | 2 | 0 | This is a review article that discusses glucocorticoid pharmacokinetics generally and presents simulations for methylprednisolone, but it does not report original quantitative PK parameter values for dexamethasone. |
| PGx | Deb_2023 | not_relevant | 0 | 0 | The paper reports in silico drug-drug interaction simulations, not pharmacogenomic effects of gene variants on dexamethasone PK/PD. |
| popPK | Derendorf_1993 | irrelevant | 0 | 0 | no_text gate: only 74 chars of text extracted (&lt; 400) |
| popPK | Dosne_2023 | irrelevant | 0 | 0 | The study reports population pharmacokinetic parameters for daratumumab, while dexamethasone is only a co-administered drug in the combination regimen. |
| PD | Dosne_2023 | not_relevant | 0 | 0 | The paper reports population PK and exposure-response analyses for daratumumab, not dexamethasone. |
| PGx | Farooq_2016 | not_relevant | 0 | 0 | The paper investigates the induction of CYP2D6 by corticosteroids in vitro, not the effect of a gene variant on the PK/PD of dexamethasone. |
| PGx | Fischer_1990 | not_relevant | 0 | 0 | The paper investigates the metabolism of fluperlapine, not dexamethasone, and does not report pharmacogenomic effects on dexamethasone PK/PD. |
| popPK | Gawarammana_2011 | irrelevant | 0 | 0 | The paper is a review of paraquat poisoning where dexamethasone is only mentioned as a co-administered immunosuppressant, with no pharmacokinetic parameters reported for dexamethasone. |
| PGx | Gentile_1996 | not_relevant | 0 | 0 | The study investigates in vitro metabolism and CYP3A4 inhibition but does not report pharmacogenomic effects of specific gene variants on PK/PD parameters. |
| PGx | Gonzalez_1987 | not_relevant | 0 | 0 | The paper focuses on the characterization of the debrisoquine 4-hydroxylase gene (P450db1) in rats and does not report pharmacokinetic or pharmacodynamic parameters for dexamethasone. |
| PGx | Gourdeau_1983 | not_relevant | 0 | 0 | The paper studies alpha-fetoprotein in guinea pigs and mentions dexamethasone only as a suppressor of AFP levels, without reporting any pharmacogenomic effects on dexamethasone PK/PD. |
| popPK | Hanafin_2025 | irrelevant | 0 | 0 | The study focuses on the exposure-response analysis of belantamab mafodotin, with dexamethasone serving only as a co-administered agent in the regimen without any reported pharmacokinetic parameters for dexamethasone itself. |
| PD | Hanafin_2025 | not_relevant | 0 | 0 | The paper reports an exposure-response analysis for belantamab mafodotin, not dexamethasone. |
| PGx | Hatano_2022 | not_relevant | 0 | 0 | The paper reports a drug-drug interaction (aprepitant inhibiting CYP3A4) affecting dexamethasone, not a pharmacogenomic effect based on a gene variant or genotype. |
| PGx | Hedrich_2016 | not_relevant | 0 | 0 | The paper is a review of CYP2B6-mediated drug-drug interactions and does not report specific pharmacogenomic effects on the PK or PD of dexamethasone. |
| PGx | Heo_2017 | not_relevant | 0 | 0 | The paper reviews rolapitant and mentions dexamethasone only as a co-administered drug, without reporting any pharmacogenomic effects on dexamethasone PK/PD. |
| PGx | Hibino_2022 | not_relevant | 2 | 5 | The study evaluates CYP3A activity using endogenous markers (testosterone/cholesterol) and reports genotype-dependent changes in these markers, but it does not report pharmacokinetic or pharmacodynamic parameters of dexamethasone itself. |
| PGx | Himes_2014 | not_relevant | 2 | 0 | The paper identifies a gene (CRISPLD2) responsive to dexamethasone and associated with clinical outcomes, but it does not report how a specific genotype changes a pharmacokinetic or pharmacodynamic parameter of dexamethasone. |
| PGx | Holt_1994 | not_relevant | 0 | 0 | The paper studies dendritic cell turnover using dexamethasone as a depleting agent, not the pharmacokinetics or pharmacodynamics of dexamethasone itself. |
| PGx | Horiuchi_2024 | not_relevant | 0 | 0 | The paper focuses on in vitro culture media optimization for cardiotoxicity evaluation and does not report pharmacogenomic effects on dexamethasone PK/PD. |
| PGx | Ikushiro_1995 | not_relevant | 0 | 0 | The paper studies drug-induced expression of UGT enzymes in rats, not the effect of a gene variant on dexamethasone pharmacokinetics or pharmacodynamics. |
| PGx | Irizar_1995 | not_relevant | 0 | 0 | The paper studies CYP expression in obese rats and mentions dexamethasone only as an inducer agent, not as the drug of interest for PK/PD analysis. |
| PGx | Iwamoto_2010 | not_relevant | 0 | 0 | The paper investigates a drug-drug interaction (bortezomib and itraconazole) and does not report any pharmacogenomic effects on dexamethasone PK/PD parameters. |
| PGx | Jakob_1995 | not_relevant | 0 | 0 | The paper studies the regulation of aromatase expression by dexamethasone in cell lines, not the effect of genetic variants on dexamethasone pharmacokinetics or pharmacodynamics. |
| popPK | Koiwai_2021 | irrelevant | 0 | 0 | The study focuses on the PK/PD of isatuximab, with dexamethasone serving only as a co-administered background therapy without specific PK parameter estimation. |
| PD | Koiwai_2021 | not_relevant | 0 | 0 | The paper reports PK/PD modeling for isatuximab (and its combinations), but does not provide specific numeric PD parameters or exposure-response relationships for dexamethasone. |
| popPK | Krzyzanski_2024 | irrelevant | 0 | 0 | no_text gate: only 68 chars of text extracted (&lt; 400) |
| PD | Krzyzanski_2024 | not_relevant | 0 | 0 | The paper describes a pharmacodynamic model for cell trafficking but does not report any exposure-response or dose-response relationship for dexamethasone. |
| PGx | Lerman_2019 | not_relevant | 0 | 0 | The paper is a general review of pediatric ambulatory anesthesia and does not report specific pharmacogenomic effects on dexamethasone PK/PD parameters. |
| PGx | Li_2018 | not_relevant | 0 | 0 | The paper investigates the role of CYP3A4 in dictamnine-induced hepatotoxicity; dexamethasone is used only as a CYP3A4 inducer, not as the drug of interest for pharmacogenomic analysis. |
| PGx | Li_2020 | not_relevant | 0 | 0 | The paper studies the metabolism and pharmacodynamics of sinomenine, not dexamethasone, and does not report pharmacogenomic effects. |
| PGx | Li_2025 | not_relevant | 0 | 0 | The paper reports a population pharmacokinetic study of dexamethasone in pediatric ALL patients, focusing on covariates like weight and asparaginase use, but does not report any pharmacogenomic effects (gene variants/genotypes) on PK or PD parameters. |
| popPK | Luo_2022 | irrelevant | 0 | 0 | The study reports population pharmacokinetic parameters for daratumumab, not dexamethasone, which is only a co-administered drug in the treatment regimen. |
| PD | Luo_2022 | not_relevant | 0 | 0 | The paper focuses on the pharmacokinetics and exposure-response of daratumumab, not dexamethasone. |
| PGx | Miyauchi_2022 | not_relevant | 0 | 0 | The paper investigates protein-protein interactions between CYP3A4 and UGTs, not the effect of a specific gene variant or genotype on dexamethasone pharmacokinetics or pharmacodynamics. |
| PGx | Miyaura_1983 | not_relevant | 0 | 0 | The paper studies the cooperative pharmacodynamic effect of dexamethasone and vitamin D3 on cell differentiation in leukemia cells, but does not report any pharmacogenomic effects (gene variants/genotypes) on PK or PD parameters. |
| PGx | Nemoto_1995 | not_relevant | 0 | 0 | The paper investigates the maintenance of Cyp2b gene expression in mouse hepatocyte cultures and the effect of dexamethasone on that expression, but it does not report a pharmacogenomic effect of a gene variant on the PK or PD of dexamethasone. |
| PGx | Nerurkar_1993 | not_relevant | 0 | 0 | The paper investigates CYP450 substrate specificity for methoxyresorufin and benzyloxyresorufin in rodents, not the pharmacogenomics of dexamethasone. |
| popPK | Papathanasiou_2025 | irrelevant | 0 | 0 | The study reports pharmacokinetic parameters for belantamab mafodotin and its payload cys-mcMMAF, not for dexamethasone, which is only a co-administered drug in combination regimens. |
| popPK | Passey_2018 | irrelevant | 0 | 0 | The paper is a review of the pharmacology of elotuzumab, where dexamethasone is only a co-administered comparator drug, and no PK parameters for dexamethasone are reported. |
| PGx | Paudel_2019 | not_relevant | 0 | 0 | The study investigates drug-drug interactions (CYP3A modulation) on loxoprofen PK, not pharmacogenomic effects on dexamethasone. |
| popPK | Perez-Ruixo_2007 | irrelevant | 0 | 0 | The study reports population pharmacokinetic parameters for trabectedin, not dexamethasone, which is only mentioned as a concomitant medication affecting trabectedin clearance. |
| PGx | Peterson_1986 | not_relevant | 0 | 0 | The paper studies disease states (Addison's/Cushing's) and dexamethasone suppression in dogs, but does not report any genetic variants or pharmacogenomic effects on PK/PD parameters. |
| PGx | Prerostova_2020 | not_relevant | 0 | 0 | The paper studies plant physiology (Arabidopsis) and uses dexamethasone only as a chemical inducer for transgene expression, not as a drug for pharmacokinetic/pharmacodynamic analysis in humans. |
| PGx | Puisset_2004 | not_relevant | 0 | 0 | The study reports no significant difference in pharmacokinetic parameters between genotypes. |
| PGx | Puisset_2005 | not_relevant | 0 | 0 | The study tests CYP3A5 and ABCB1 genotypes as covariates for vinorelbine clearance but explicitly states they were not associated, and dexamethasone is used only as a probe drug. |
| PGx | Relling_1994 | not_relevant | 0 | 0 | The paper investigates the metabolism of epipodophyllotoxins (etoposide/teniposide) by CYP3A4, using dexamethasone only as a competitive inhibitor to identify the enzyme, rather than reporting pharmacogenomic effects on dexamethasone's PK/PD. |
| PGx | Savelieva_2015 | not_relevant | 0 | 0 | The paper reports population pharmacokinetics of panobinostat, not dexamethasone, and does not report pharmacogenomic effects. |
| PGx | Schoffelen_2018 | not_relevant | 0 | 0 | The paper discusses drug-drug interactions involving aprepitant, not pharmacogenomic effects on dexamethasone. |
| PGx | Shimamoto_2021 | not_relevant | 0 | 0 | The study investigates dose-dependent pharmacokinetics and antiemetic effects of dexamethasone in cancer patients but does not report any gene variants, genotypes, or pharmacogenomic effects. |
| PGx | Shou_2008 | not_relevant | 0 | 0 | The paper focuses on CYP3A4 induction modeling and drug-drug interactions, not on pharmacogenomic effects of gene variants on dexamethasone PK/PD. |
| PGx | Sidhu_1995 | not_relevant | 0 | 0 | The paper investigates the effect of dexamethasone on CYP gene expression in rat hepatocytes, not the effect of a human gene variant on dexamethasone pharmacokinetics or pharmacodynamics. |
| PGx | Sidhu_1995_2 | not_relevant | 0 | 0 | The paper investigates cAMP-mediated regulation of CYP gene expression in rat hepatocytes and does not report pharmacogenomic effects on dexamethasone PK or PD parameters. |
| popPK | Snaterse_2023 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of androgen receptor mutations and ligand binding, not a pharmacokinetic study reporting disposition parameters for dexamethasone. |
| popPK | Song_2021 | relevant | 10 | 2 | The paper reports a cross-species PK model for dexamethasone with specific aggregate statistics (mean CL, CV, partition coefficient), but the specific numeric parameter values for individual species are not listed in the provided text. |
| PGx | Suntornlohanakul_2026 | not_relevant | 0 | 0 | The paper investigates temporal changes in cortisol secretion and outcomes in adrenal incidentalomas, with no mention of dexamethasone pharmacokinetics or pharmacodynamics or genetic variants. |
| PGx | Terrier_2025 | not_relevant | 0 | 0 | The paper investigates a drug-drug interaction (dexamethasone inducing CYP3A4/P-gp affecting apixaban/rivaroxaban), not a pharmacogenomic effect (gene variant) on dexamethasone's PK/PD. |
| PGx | Tomlinson_1997 | not_relevant | 0 | 0 | The study examines species differences in dexamethasone metabolism in vitro, not the effect of human gene variants or genotypes on PK/PD parameters. |
| PGx | Urien_2011 | not_relevant | 0 | 0 | The study examines the effect of dexamethasone and gene variants on the pharmacokinetics of etoposide, not dexamethasone. |
| PGx | Van_2018 | not_relevant | 0 | 0 | The paper discusses the pharmacokinetics of panobinostat and its drug-drug interaction with dexamethasone via CYP2D6 inhibition, but it does not report any pharmacogenomic effects (gene variants) on dexamethasone PK/PD. |
| PGx | Vitellius_2018 | not_relevant | 2 | 0 | The paper is a review of glucocorticoid receptor pathophysiology and mutations, not a study reporting specific pharmacokinetic or pharmacodynamic parameter changes for dexamethasone based on genotype. |
| popPK | Wen_2024 | relevant | 10 | 0 | The paper describes a population pharmacokinetic model for dexamethasone, but the specific numeric parameter values (CL, V, etc.) are not present in the provided abstract text. |
| PGx | White_1995 | not_relevant | 0 | 0 | The paper studies the metabolism of tamoxifen, not dexamethasone, and does not report pharmacogenomic effects on dexamethasone PK/PD. |
| PGx | Xiao_2020 | not_relevant | 0 | 0 | The study investigates the effect of CYP3A4 modulation on triptolide-induced hepatotoxicity, using dexamethasone only as a CYP3A4 inducer, and does not report pharmacogenomic effects on dexamethasone's PK or PD parameters. |
| PGx | Xu_2018 | not_relevant | 0 | 0 | The study investigates the effect of dexamethasone (as a CYP3A inducer) on the pharmacokinetics of triptolide, not the effect of a gene variant on dexamethasone's pharmacokinetics or pharmacodynamics. |
| PGx | You_2021 | not_relevant | 0 | 0 | The paper investigates the metabolism of gelsemine by CYP3A4, using dexamethasone only as an inducer to test the pathway, rather than reporting a pharmacogenomic effect on dexamethasone's own PK/PD parameters. |
| PGx | Zhang_2003 | not_relevant | 0 | 0 | The paper characterizes CYP450 expression and induction in mouse intestine but does not report pharmacokinetic or pharmacodynamic parameters of dexamethasone itself. |
| popPK | Zhang_2022 | irrelevant | 0 | 0 | no_text gate: only 72 chars of text extracted (&lt; 400) |
| PGx | Zhang_2022 | not_relevant | 0 | 0 | The paper is a systematic review of methotrexate pharmacokinetics, not dexamethasone. |
| PGx | Zimmerman_2018 | not_relevant | 0 | 0 | The study investigates the pharmacodynamics of dexamethasone (adrenal suppression) in different dog breeds and correlates ALP levels with SNPs, but it does not report how a specific gene variant alters the PK or PD parameters of dexamethasone itself. |
| popPK | Zufferey_2024 | irrelevant | 0 | 0 | This is a systematic review and network meta-analysis of clinical efficacy (analgesia duration) of dexamethasone as an adjuvant, not a pharmacokinetic study reporting disposition parameters like clearance or volume. |
| PGx | van_2023 | not_relevant | 0 | 0 | The study explicitly concludes that genetic variation was not a significant determinant for the reported neurobehavioral and sleep problems. |
| PGx | van_2024 | not_relevant | 0 | 0 | The paper focuses on age-related ontogeny of CYP3A4 and physiological PBPK modeling, not on specific gene variants or genotypes. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-10-04 00:16 UTC</sub>
